

**Iris Grossman, Ph.D.**  
**Vice President, Head of Early Stage Clinical Development, Teva**

Dr. Iris Grossman, VP, global Head of the Early Stage Clinical Development unit in Teva Global R&D, has dedicated her research career, in both industry and academia, to the advancement of the field of personalized medicine. In her current position she leads a novel model of patient-centric R&D, integrating active physician and patient involvement, as well as collaborative pharmacometric, bio- and digital-marker methodologies into early discovery phases through to enhanced probability of success for proof-of-concept assets. Championing innovation via the use of cutting-edge biologic and digital markers, she aims to tailor high-quality, high probability of success healthcare solutions for patients and caregivers in need. Israel's leading financial magazine, Globes Magazine, selected Dr. Grossman as one of the country's top 40 professionals under 40 years of age in 2013.

Prior to joining Teva, Dr. Grossman was CEO and president of the pharmacogenetics management consultancy IsraGene Ltd., providing services to both the pharma and biotech sectors. This followed several years of spearheading pipeline pharmacogenetic programs for industry and academia as director of pharmacogenetics at Cabernet Pharmaceuticals Inc. Dr. Grossman moved into consultancy having been responsible for running large-scale pharmacogenetic programs at GlaxoSmithKline, with an emphasis on infectious and neurological diseases.

In academia, Dr. Grossman was a key member of Professor David Goldstein's team at the Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, at Duke University. Dr. Grossman received her PhD from the Technion – Israel Institute of Technology, where her research project, conducted in collaboration with the Weizmann Institute for Science, investigated pharmacogenetic markers of multiple sclerosis treatment response.